186 related articles for article (PubMed ID: 35790816)
1. Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis.
Reiter A; Gotlib J; Álvarez-Twose I; Radia DH; Lübke J; Bobbili PJ; Wang A; Norregaard C; Dimitrijevic S; Sullivan E; Louie-Gao M; Schwaab J; Galinsky IA; Perkins C; Sperr WR; Sriskandarajah P; Chin A; Sendhil SR; Duh MS; Valent P; DeAngelo DJ
Leukemia; 2022 Aug; 36(8):2108-2120. PubMed ID: 35790816
[TBL] [Abstract][Full Text] [Related]
2. Indirect treatment comparisons of avapritinib versus midostaurin for patients with advanced systemic mastocytosis.
Pilkington H; Smith S; Roskell N; Iannazzo S
Future Oncol; 2022 Apr; 18(13):1583-1594. PubMed ID: 35114819
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis.
Reiter A; Schwaab J; DeAngelo DJ; Gotlib J; Deininger MW; Pettit KM; Alvarez-Twose I; Vannucchi AM; Panse J; Platzbecker U; Hermine O; Dybedal I; Lin HM; Rylova SN; Ehlert K; Dimitrijević S; Radia DH
Blood Adv; 2022 Nov; 6(21):5750-5762. PubMed ID: 35640224
[TBL] [Abstract][Full Text] [Related]
4. Avapritinib for advanced systemic mastocytosis.
Gotlib J; Reiter A; DeAngelo DJ
Blood; 2022 Oct; 140(15):1667-1673. PubMed ID: 35877999
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial.
Gotlib J; Reiter A; Radia DH; Deininger MW; George TI; Panse J; Vannucchi AM; Platzbecker U; Alvarez-Twose I; Mital A; Hermine O; Dybedal I; Hexner EO; Hicks LK; Span L; Mesa R; Bose P; Pettit KM; Heaney ML; Oh ST; Sen J; Lin HM; Mar BG; DeAngelo DJ
Nat Med; 2021 Dec; 27(12):2192-2199. PubMed ID: 34873345
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.
DeAngelo DJ; Radia DH; George TI; Robinson WA; Quiery AT; Drummond MW; Bose P; Hexner EO; Winton EF; Horny HP; Tugnait M; Schmidt-Kittler O; Evans EK; Lin HM; Mar BG; Verstovsek S; Deininger MW; Gotlib J
Nat Med; 2021 Dec; 27(12):2183-2191. PubMed ID: 34873347
[TBL] [Abstract][Full Text] [Related]
7. Avapritinib for Systemic Mastocytosis.
Bose P; Verstovsek S
Expert Rev Hematol; 2021 Aug; 14(8):687-696. PubMed ID: 34289787
[TBL] [Abstract][Full Text] [Related]
8. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
Shomali W; Gotlib J
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174
[TBL] [Abstract][Full Text] [Related]
9. Avapritinib in the Treatment of Systemic Mastocytosis: an Update.
Below S; Michaelis LC
Curr Hematol Malig Rep; 2021 Oct; 16(5):464-472. PubMed ID: 34580817
[TBL] [Abstract][Full Text] [Related]
10. Systemic mastocytosis with an associated hematologic neoplasm complicated by recurrent anaphylaxis: Prompt resolution of anaphylaxis with the addition of avapritinib.
Kudlaty E; Perez M; Stein BL; Bochner BS; Kuang FL
J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2534-2536. PubMed ID: 33677080
[No Abstract] [Full Text] [Related]
11. Advanced Systemic Mastocytosis with associated haematological neoplasm: Treatment with avapritinib can facilitate successful bridge to allogeneic haematopoietic cell transplant.
Sriskandarajah P; McLornan DP; Oni C; Wilson AJ; Woodley C; Ciesielska M; Raj K; Dillon R; Ethell M; Chacko J; Orchard K; Radia DH
Curr Res Transl Med; 2023; 71(3):103398. PubMed ID: 37331225
[TBL] [Abstract][Full Text] [Related]
12. Avapritinib versus Placebo in Indolent Systemic Mastocytosis.
Gotlib J; Castells M; Elberink HO; Siebenhaar F; Hartmann K; Broesby-Olsen S; George TI; Panse J; Alvarez-Twose I; Radia DH; Tashi T; Bulai Livideanu C; Sabato V; Heaney M; Van Daele P; Cerquozzi S; Dybedal I; Reiter A; Pongdee T; Barete S; Ustun C; Schwartz L; Ward BR; Schafhausen P; Vadas P; Bose P; DeAngelo DJ; Rein L; Vachhani P; Triggiani M; Bonadonna P; Rafferty M; Butt NM; Oh ST; Wortmann F; Ungerstedt J; Guilarte M; Taparia M; Kuykendall AT; Arana Yi C; Ogbogu P; Gaudy-Marqueste C; Mattsson M; Shomali W; Giannetti MP; Bidollari I; Lin HM; Sulllivan E; Mar B; Scherber R; Roche M; Akin C; Maurer M
NEJM Evid; 2023 Jun; 2(6):EVIDoa2200339. PubMed ID: 38320129
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data.
von Mehren M; Heinrich MC; Shi H; Iannazzo S; Mankoski R; Dimitrijević S; Hoehn G; Chiroli S; George S
BMC Cancer; 2021 Mar; 21(1):291. PubMed ID: 33740926
[TBL] [Abstract][Full Text] [Related]
14. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis.
Reiter A; George TI; Gotlib J
Blood; 2020 Apr; 135(16):1365-1376. PubMed ID: 32106312
[TBL] [Abstract][Full Text] [Related]
15. Novel approaches to treating advanced systemic mastocytosis.
Gilreath JA; Tchertanov L; Deininger MW
Clin Pharmacol; 2019; 11():77-92. PubMed ID: 31372066
[TBL] [Abstract][Full Text] [Related]
16. KIT-mutated pediatric core-binding factor systemic mastocytosis-acute myeloid leukemia treated with avapritinib and decitabine.
Sheikh IN; AlQahtani S; Yin CC; McCall D; Cuglievan B; Ragoonanan D; Connors JS; Gibson A; Nunez C; Roth M; Ohanian M; Borthakur G; Garcia MB
Pediatr Blood Cancer; 2024 Apr; 71(4):e30898. PubMed ID: 38291730
[No Abstract] [Full Text] [Related]
17. Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis.
Lübke J; Naumann N; Kluger S; Schwaab J; Metzgeroth G; Evans E; Gardino AK; Lengauer C; Hofmann WK; Fabarius A; Cross NCP; Reiter A; Jawhar M
Leukemia; 2019 May; 33(5):1195-1205. PubMed ID: 30911112
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of avapritinib in refractory aggressive systemic mastocytosis: a single-patient case.
Szudy-Szczyrek A; Juda A; Kokoć A; Krupski W; Szumiło J; Hus M
Pol Arch Intern Med; 2023 May; 133(5):. PubMed ID: 36994901
[No Abstract] [Full Text] [Related]
19. Liver fibrosis and its response to avapritinib in 2 patients with systemic mastocytosis.
Cavazos K; Eswaran S; Maidlow C; Keklik Karadag F; Idilman R; Idilman I; Miller I; Shammo J; Reau N; Ustun C
Blood Adv; 2022 Oct; 6(20):5630-5633. PubMed ID: 35839085
[TBL] [Abstract][Full Text] [Related]
20. Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.
Baird JH; Gotlib J
Curr Hematol Malig Rep; 2018 Oct; 13(5):407-416. PubMed ID: 30155614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]